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ABSTRACT
Flap endonuclease-1 (FEN1) is a member of the Rad2
structure-specific nuclease family. FEN1 possesses
FEN, 50-exonuclease and gap-endonuclease
activities. The multiple nuclease activities of FEN1
allow it to participate in numerous DNA metabolic
pathways, including Okazaki fragment maturation,
stalled replication fork rescue, telomere mainten-
ance, long-patch base excision repair and apoptotic
DNA fragmentation. Here, we summarize the distinct
roles of the different nuclease activities of FEN1 in
these pathways. Recent biochemical and genetic
studies indicate that FEN1 interacts with more than
30 proteins and undergoes post-translational modi-
fications. We discuss how FEN1 is regulated via
these mechanisms. Moreover, FEN1 interacts with
five distinct groups of DNA metabolic proteins,
allowing the nuclease to be recruited to a specific
DNAmetabolic complex,suchas theDNA replication
machinery for RNA primer removal or the DNA
degradosome for apoptotic DNA fragmentation.
Some FEN1 interaction partners also stimulate
FEN1 nuclease activities to further ensure efficient
action in processing of different DNA structures.
Post-translational modifications, on the other hand,
may be critical to regulate protein–protein inter-
actions and cellular localizations of FEN1. Lastly,
we also review the biological significance of FEN1
as a tumor suppressor, with an emphasis on
studies of human mutations and mouse models.
INTRODUCTION
DNA replication, recombination and repair are essential
for maintaining the integrity of genomes. These DNA
metabolic pathways create various DNA intermediates
that must also be efﬁciently processed, otherwise severe
genomic instability will result. Many of the DNA inter-
mediates formed are bifurcated nucleic acid structures that
require nucleases to recognize the structure of the inter-
mediate and to only cleave the appropriate phosphate
diester, regardless of sequence. A nuclease that typiﬁes
these qualities is ﬂap endonuclease-1 (FEN1), which is
the archetypal member of the Rad2 nuclease family
(1,2). FEN1 is a structure-speciﬁc metallonuclease best
known for its essential roles in the penultimate steps of
Okazaki fragment maturation and long-patch base
excision repair (BER) (1,3,4). Furthermore, FEN1 has
also been implicated in other major DNA metabolic
pathways, including resolution of tri-nucleotide repeat
sequence-derived secondary structures, rescue of stalled
DNA replication forks, maintenance of telomere stability
and apoptotic fragmentation of DNA (5–10).
How FEN1 is involved in multiple pathways that are
seemingly contradictory (i.e. genome maintenance versus
apoptotic DNA fragmentation) has been of interest to our
lab and others. The multiple functions of FEN1 may be
regulated via three interplaying mechanisms: (i) formation
of complexes with different protein partners, (ii) cellular
compartmentalization and (iii) post-translational modiﬁ-
cations. First, FEN1 is known to rely on interactions with
other DNA metabolic proteins for recruitment to different
machineries for DNA replication, repair or degradation.
Some of these interaction partners of FEN1 also stimulate
its nuclease activities to facilitate efﬁcient processing of
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proteins from various DNA metabolic pathways have
been identiﬁed as interacting with FEN1. Second, FEN1
was shown to localize to the nucleus in a DNA damage
and cell cycle-dependent manner (11), implicating the
dynamic nuclear localization of FEN1 as playing an
important role in mediating its functions in DNA replica-
tion and repair. More recently, FEN1 was shown to
super-accumulate in the nucleolus, where it is thought to
maintain the stability of tandem repeats of ribosomal
DNA (12). Furthermore, FEN1 was also shown to
localize to the mitochondrion, where it plays an important
role in mitochondrial DNA (mtDNA) replication and
repair (13). Last, FEN1 can be acetylated, phosphorylated
and methylated, and these post-translational modiﬁca-
tions may be important for the regulation of the
nuclease activities, protein partner selection and/or
subcellular compartmentalization (14–16).
FEN1 displays a severe mutator phenotype in yeast
when deleted (17), and therefore, functional deﬁciency
of FEN1 has been suggested to cause genomic instability
and predisposition to cancer in mammals. Recently, a
group of FEN1 mutations was identiﬁed in human
cancer specimens (9). Most of these mutations abrogated
the ability of FEN1 to cleave model exonuclease (EXO)
and gap-endonuclease substrates in vitro, while retaining
the ability to cleave FEN substrates (9). To demonstrate
the etiological signiﬁcance of these somatic mutations, a
mouse line that harbors an E160D Fen1 point mutation
was generated to represent the mutations identiﬁed
in human cancers (9). Selective elimination of the EXO
and GEN hydrolytic speciﬁcities led to frequent spontan-
eous mutations and accumulation of incompletely
digested DNA fragments in apoptotic cells. In addition,
the mutant mice were predisposed to autoimmunity,
chronic inﬂammation and cancers. Thus, the mutator
phenotype results in the initiation of cancer, whereas
chronic inﬂammation promotes cancer progression (9).
MULTIPLE STRUCTURE-SPECIFIC NUCLEASE
ACTIVITIES AND THEIR BIOLOGICAL FUNCTIONS
Mammalian FEN1 was ﬁrst characterized as DNase IV,
an obligate 50–30 dsDNA exonuclease, during a survey of
nucleases from rabbit tissues (18). After bacterial 50–30
exonucleases in eubacteria were discovered to be ﬂap
structure-speciﬁc nucleases (19), a mammalian FEN1
homolog was reported and determined to be the same as
DNase IV, discovered >20 years earlier (20). Since then,
much work to determine how FEN1 recognizes its sub-
strates has been conducted (21–31). The predominantly
accepted model for mammalian FEN1 has been the
track-down model (27,32). Based on studies in which
access to the 50-end of the ﬂap was blocked by
streptavidin, FEN1 was postulated to initially recognize
the free 50-end of the ﬂap structure and then track down
the 50-ﬂap until reaching the double-stranded DNA
(dsDNA) region where it then cleaved the scissile phos-
phate (27,32). Despite the popularity of the track-down
model, more recent biochemical evidence suggests that
mammalian FEN1 ﬁrst recognizes the dsDNA two-way
junction, and then places the scissile phosphate in the
active site by threading or clamping the single-stranded
DNA (ssDNA) ﬂap (22,33). The latter mechanism, ﬁrst
proposed by Joyce and co-workers for eubacterial
FEN1 homologs (31), is more consistent with the ability
of FEN1 to perform exonucleolytic cleavage and is likely
the best description of the protein’s substrate recognition
mechanism in vitro. Furthermore, the latter model is also
consistent with the notion that Rad2 nucleases are a
family of DNA junction recognition enzymes (34).
In contrast to previous reports that the presence of
dsDNA in the ﬂap strand prevented FEN1 from
cleaving (27,35), two separate studies determined that
FEN1 has GEN activity, which cleaves single-stranded
regions with gaps of four or more nucleotides (6,10).
CRN-1, the FEN1 homolog in Caenorhabditis elegans,
was shown to cleave the template strand of a gapped
DNA duplex that resembled an intermediate DNA struc-
ture generated during apoptotic DNA fragmentation (6),
whereas human FEN1 was found to cleave the template
strand of gapped DNA fork and bubble substrates that
mimic a stalled DNA replication fork. Furthermore, the
presence of intrinsic FEN1 GEN activity was supported
by mutational analysis. FEN1 mutations such as R70A,
R326A/R327A, K244A/R245A at the dsDNA binding
region abolished the EXO and/or GEN activities, but
had little effect on the FEN activity (26). The E178A
mutation, which occurs near the active center and the
dsDNA binding region, was shown to eliminate 95% of
the wild-type GEN activity, but retained most of its
50-FEN activity (10). In contrast, another mutant,
Q112R, identiﬁed in human cancer cells and located
in the helical loop involved in ssDNA binding,
was observed to increase GEN activity by 3-fold while
retaining wild-type levels of the other two activities (9).
Characterization of the hydrolytic speciﬁcities of FEN1
has provided mechanistic insights into how a nuclease
with a single active site can perform three separate
activities. Kinetic analysis revealed that FEN1 displays
its highest catalytic efﬁciency on the so-called double
ﬂap substrate, which is characterized by having a
50-ssDNA ﬂap of any length and a single nucleotide
30-ﬂap (26). Consistent with this, equilibrating ﬂap
substrates, which can adopt a double ﬂap conformation,
are thought to be the in vivo FEN1 substrate (21,25).
In comparison to the catalytic efﬁciency on double ﬂap
substrates, the kcat/KM value for the EXO activity on a
nick substrate (i.e. no 50-o r3 0-ﬂap) was  15-fold less than
the FEN activity, whereas the efﬁciencies of the GEN
activity on gapped-fork and gapped-duplex substrates
were 6- and 250-fold less than the FEN activity, respect-
ively (26). Despite the wide range of cleavage efﬁciencies,
these three manners of hydrolyzation (FEN, EXO and
GEN) all share a commonality: predominant incision
1nt into the downstream dsDNA with minor cleavages
50 or 30 of this site. Because structural studies of FEN1
revealed that FEN1 contains two dsDNA-binding regions
and a helical arch associated with ssDNA-binding (36),
the ability of FEN1 to hydrolyze a wide range of
substrates using the same active center was explained by
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strates (26). Moreover, cleavage patterns can be explained
if the downstream dsDNA region (i.e. dsDNA that is
incised) is bound by the H3TH motif with the active site
in proximity to the scissile phosphate and subsequent
placement of other substrate structural elements with the
upstream dsDNA binding region and/or helical arch. In
addition, the efﬁciency of cleavage could also be partially
rationalized using this model (26). These ﬁndings support
the concept that FEN1 employs distinct DNA
substrate-binding modes to interact with different DNA
substrates.
The ability of FEN1 to cleave nick and gapped-fork
substrates is greatly enhanced by the addition of a 1nt
30-ﬂap, similar to that observed with ﬂap substrates (22).
Recently, we and others have conducted more detailed
kinetic studies with various FEN1 substrates with a
30-ﬂap. These studies suggest that the paramount struc-
tural feature of substrates recognized by FEN1 is a
30-ﬂap (22,30) rather than a 50-ﬂap (27). Although it was
previously known that substrates bearing a 30-ﬂap were
cleaved at a faster rate by FEN1 (37), the presence of
the 30-ﬂap was further shown to increase single-turnover
rates of catalysis in addition to its role in increasing
enzyme-substrate afﬁnity (22,30,37). Thus, occupation of
30-ﬂap binding pocket is not only critical for initial sub-
strate capture, but for increasing subsequent ﬁrst order
rates of reaction after formation of the enzyme substrate
complex by an unknown mechanism. With an increase in
kcat and concomitant decrease in KM observed with double
ﬂap substrates, it is not surprising that the second order
rate constants of reaction with double ﬂap substrates
approached levels suggesting that encounter of substrate
and enzyme is rate-limiting.
FEN activity is critical for RNA primer removal and
BER pathways
FEN activity, the most dominant activity of FEN1, is
considered to play a major role in RNA primer removal
during Okazaki fragment maturation of lagging strand
DNA replication, as well as in removal of ﬂap structures
formed during long-patch BER. Details of the role of
FEN1 in these two classical pathways were previously
reviewed (1,4,38,39). It should be noted that the mechan-
isms of RNA primer removal in human and yeast are
likely different. During lagging strand DNA synthesis in
eukaryotic cells, Pola creates RNA/DNA primers contain-
ing  10nt of RNA and 10–20nt of DNA to initiate
synthesis of Okazaki fragments. In human and other
mammalian cells, Pold displaces the RNA/DNA primer
to create a ﬂap for FEN1 to cleave; however, the size of
the ﬂap generated by strand-displacement synthesis in
mammals is still unknown. The essential role of FEN1
in RNA/DNA primer removal in mammalian cells has
been validated by several in vivo studies using mouse
models that showed that FEN1 deﬁciency causes defects
in DNA replication, failure of cell proliferation and
embryonic lethality (40–42). In contrast, deletion of
RAD27 (FEN1 yeast homolog) is tolerated in yeast,
implicating the involvement of other nucleases in this
process (43,44). Furthermore, recent studies suggest that
long ﬂap structures occur frequently during Okazaki
fragment maturation in yeast. The displacement of ﬂaps
longer than 30nt during Okazaki fragment maturation in
yeast is envisioned to attract RPA, which inhibits FEN1,
but recruits Dna2 endonuclease to cleave a large portion
of the primer, as Dna2 can efﬁciently clamp onto the site.
The cleavage of the long ﬂap structure by the Dna2/RPA
complex generates a short ﬂap ( 5–7nt) that resists
binding and cleavage by RPA and Dna2, respectively
(45). The FEN1 nuclease can then precisely remove the
remaining ﬂap to produce a substrate for ligation.
However, the RPA-governed sequential actions of Dna2
and FEN1 for Okazaki fragment processing may only
occur in yeast, and not higher eukaryotes. In mammalian
cells, DNA2 predominantly migrates into mitochondria
(46), and the residual nuclear DNA2 is not associated
with DNA replication foci (46,47), suggesting that
DNA2 is not a primary component in the DNA replica-
tion machinery. These ﬁndings support the hypothesis that
FEN1 may be the primary nuclease in nuclear RNA
primer removal in mammals, whereas coordinated
actions of FEN1 and Dna2 are important in this process
in yeast.
The FEN activity is also necessary for repairing DNA
lesions that have an oxidatively-damaged sugar moiety,
which cannot be removed by the dRP lyase of Polb
(13,48). In such a case, a few nucleotides are added by
polymerase b or d to produce a short ﬂap, which is sub-
sequently removed by FEN1 in complex with the
processivity factor proliferating cell nuclear antigen
(PCNA) (49). This alternative FEN1/PCNA-dependant
BER pathway is termed long-patch BER (LP-BER) (49).
A recent study by Wilson’s group further suggested that
the FEN and EXO activities of FEN1 might work
together because the Polb activity is only active on
DNA duplexes that contain a gap, but not a nick.
Therefore, the EXO activity of FEN1 may be important
for cleaving the nick substrate and generating an optimal
gap intermediate for Polb during LP-BER (50). The short
ﬂap resulting from displacement DNA synthesis would
then be removed by the FEN activity. In support of this
model, the E160D FEN1 mutation, which speciﬁcally
eliminates the EXO activity, causes mouse embryonic
ﬁbroblasts to be sensitive to DNA damaging agents such
as methylmethane sulfonate (9).
Concerted action of EXO and GEN activities for
resolution of DNA hairpin structures and apoptotic DNA
fragmentation
The two other ‘minor’ activities of FEN1 (EXO and
GEN) may be important for other DNA metabolic
pathways, including resolution of tri-nucleotide repeat
(TNR) sequence-derived secondary structures and apop-
totic DNA fragmentation. Much evidence indicates that
FEN1 efﬁciently cleaves ssDNA ﬂaps, but inefﬁciently
processes ﬂaps that adopt secondary structures and lack
a3 0-ﬂap (27,51). However, absence of Fen1 in yeast results
in a signiﬁcant increase in TNR expansion (51).
Furthermore, the expression level of FEN1 has recently
Nucleic AcidsResearch, 2011, Vol.39,No. 3 783been shown to correlate with TNR expansion in mice (52).
Therefore, three possibilities exist: (i) TNRs do not always
form stable secondary structures, (ii) FEN1 uses an alter-
native approach to resolve the secondary structures (5,8)
or (iii) increased unequal sister chromatid exchange, a
phenotype associated with FEN1 deletion (53), causes
TNR contraction and expansion. We have tested the hy-
pothesis that concerted action of the EXO and GEN
activities of FEN1 plays a role in resolution of secondary
structures formed by (CTG)n and (GAA)n repeats (8).
Using a yeast FEN1 point mutant, E176A, which is
deﬁcient in EXO and GEN activities but retains almost
all of its FEN activity, we showed severe defects in the
ability of this mutant to cleave various TNR intermediate
substrates (8). Precise knock-in of the E176A point
mutation in yeast caused an increase in both the expansion
and fragility of a (CTG)n tract in vivo (8). Taken together,
the combined biochemical and genetic analyses suggested
that although FEN activity is important for ssDNA-ﬂap
processing, the EXO and GEN activities may also contrib-
ute to the suppression of TNR contraction and expansion.
Therefore, we proposed the following model: in the
presence of TNRs, which can base pair and fold back to
form hairpin structures or loops, FEN1 endonucleolytic
cleavage is suppressed. This increases the half-life of
the ﬂap, which can form an internal loop and ligate
into the genome, resulting in TNR expansion. However,
as a back-up approach, the EXO activity of FEN1 can
remove the hairpin nucleotides in a gap or ssDNA/
dsDNA junction, on which GEN cleavage can occur
(Figure 1).
The ﬁnding that FEN1 plays an important role in
suppression of TNR expansion in yeast has stirred great
interest in exploring whether FEN1 is critical in destabil-
ization of the TNR hairpin structures and whether deﬁ-
ciency of FEN1 in humans contributes to TNR-related
genetic diseases, including Huntington disease (HD)
(51,54). However, whether FEN1 deﬁciency plays a role
in development of HD or other TNR-related diseases
remains controversial. A survey for FEN1 mutations
in human HD patients did not identify any mutations in
this subset of patients (55). More recently, another study
showed that haploinsufﬁciency of FEN1 did not accelerate
the expansion of (CTG)n (CAG)n (n: 105–110) repeats,
which resemble the myotonic dystrophy type 1 disease
locus, in mice (129Ola genetic background) (56). On the
other hand, Yang and Freudenreich (57) showed that
haploinsufﬁciency of FEN1 promotes expansion of
(CAG)120 repeats that mimic the human HD locus in
mice (CBAxC57BL/6 genetic background. We note that
these two TNR mouse models have different genetic back-
grounds, which may contribute to the discrepancies in
TNR phenotypes. It is likely that FEN1 mutations on
their own may not signiﬁcantly promote TNR expansions
or contractions due to redundant pathways in mainten-
ance of TNR stability, but in combination with other
genetic mutations, FEN1 deﬁciency may contribute to
TNR instabilities and related diseases in humans.
Supporting this view, a previous study showed that micro-
satellite instabilities were not promoted in mice heterozy-
gous for FEN1 knockout, but haploinsufﬁciency of FEN1
in a genetic background with an adenomatous polyposis
coli (APC) gene mutation did signiﬁcantly increase micro-
satellite instabilities (40).
The concerted action of the EXO and GEN activities of
FEN1 may also play a role in oligonucleosomal fragmen-
tation of chromosomes in apoptotic cells (58). In collab-
oration with the Xue group, we have shown that crn-1, a
C. elegans homolog of human FEN1, is important for
apoptosis (6). Reduction of CRN-1 activity by RNA inter-
ference resulted in cell death phenotypes similar to those
displayed by a mutant lacking the mitochondrial endo-
nuclease CPS-6/endonuclease G (Endo G). We proposed
that CRN-1 associates and cooperates with CPS-6 to
promote stepwise DNA fragmentation, whereby CPS-6
nicks the dsDNA and the EXO activity of CRN-1 subse-
quently removes a few nucleotides from the 50-end to
generate a gap. The GEN activity of CRN-1 then cuts
the template strand at the DNA gap, leading to DNA
fragmentation (Figure 1). Supporting this hypothesis, the
EXO- and GEN-deﬁcient FEN1 mutation, E160D,
retards the disposal of apoptotic DNA and results in
anti-dsDNA circulating in the blood system of mutant
mice (9).
Figure 1. DNA metabolic pathways and corresponding biochemical activities of FEN1. FEN1 is implicated in six DNA metabolic pathways. Its
FEN activity is essential for cleaving the single-stranded ﬂap resulting from displacement DNA synthesis during RNA primer removal and in
long-patch base excision repair. The 50-EXO activity of FEN1 removes a few nucleotides from 50-blunt ends or nicks to generate a gap, which can be
cut by the gap-endonuclease (GEN) activity of FEN1 at the opposite template strand. The concerted action of the EXO and GEN activities produces
DNA double strand breaks, which are important for removal of hairpin structures, rescue of stalled replication forks and apoptotic DNA frag-
mentation. FEN1 activities may also be important for maintenance of the telomere, but how they act at the chromosome end is unknown. Arrows:
FEN1 nuclease cleavage sites; Red: newly synthesized RNA and DNA; yellow circles: damaged DNA or cross-links.
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FEN1 has been implicated in the rescue of stalled replica-
tion forks caused by exogenous physical and chemical
insults. FEN1 forms a complex with WRN in response
to DNA damage that arrests replication forks (10,59), sug-
gesting a role of FEN1 in resolution of stalled replication
forks. Results from the Brosh group suggest that the FEN
activity may be important for cleaving regressed replica-
tion forks to resolve the chicken foot structure (59).
Alternatively, stalled replication forks may be restarted
via the break-induced recombination pathway, in which
a DNA double-stranded break (DSB) is created on the
stalled replication fork to initiate downstream recombin-
ation cascades (60). ssDNA gaps that accumulate on
stalled replication forks are potential targets for endo-
nucleases to generate DSBs. In such a case, the GEN
activity, which is dramatically stimulated by WRN,
cleaves the fork to initiate the break-induced recombin-
ation (10). Human FEN1, but not the GEN-deﬁcient
mutant, E178A, is capable of rescuing yeast fen1 null
mutants from UV- and campothecin-induced DNA
damage, indicating the importance of the GEN activity
of FEN1 in restarting stalled replication forks.
Furthermore, we have recently shown that deﬁciency in
FEN1 nuclease activities in yeast also causes defects in
replication of rDNA, in which DNA replication forks
are frequently stalled by naturally occurring fork
barriers such as DNA-binding proteins (12).
Several lines of biochemical and genetic evidence have
suggested that FEN1 plays a role in maintenance of the
integrity of GC-rich repeat DNA sequences, including
CEB-1 minisatellites, rDNA regions and telomeres.
Deletion of Rad27 in yeast causes instabilities of the
human minisatellite locus CEB1 inserted into the yeast
genome (61,62). Two models have been proposed to
explain how FEN1 deﬁciency causes minisatellite expan-
sions or contractions. In the ﬁrst model, deﬁciency in the
FEN activity leads to unprocessed 50-ﬂap structures. The
GC-rich minisatellites, such as CEB1 sequences, that are
prone to forming secondary structures, fold back and
anneal to the template strand (61,62), although such sec-
ondary structure can be processed by the concerted action
of EXO and GEN activities of FEN1 (8,26). Alternatively,
the non-cleaved DNA ﬂap may result in DNA DSBs and
trigger improper DNA recombination events, leading to
expansions or contractions (17,62).
Recently, FEN1 has also been suggested to contribute
to telomere stability in yeast (63,64) and human cells
(7,65,66). Abrogation of FEN1 function may inﬂuence
the transformation of a cell into a cancer cell by
compromising telomere stability and driving genomic in-
stability. The Steward group analyzed the telomeres of
human cancer cells after FEN1 depletion, and showed
that FEN1 is required for telomere stability in cancer
cells that rely on the alternative lengthening of telomere
(ALT) mechanism (7,65). FEN1 depletion resulted in
telomere dysfunction that was characterized by formation
of telomere dysfunction-induced foci (TIFs) and
end-to-end fusions in ALT-positive cells. In contrast, no
telomere dysfunction was observed in telomerase-positive
cells with FEN1 depletion, suggesting that ongoing tel-
omerase activity protected telomeres. The FEN1 muta-
tions affect telomere stability and genome ﬁdelity by
promoting telomere fusions and anaphase–bridge–
breakage cycles, which further drive genome instability,
thereby contributing to the transformation process
(7,65). In addition, Chai and colleagues have shown com-
plementary data indicating that FEN1 is in complex with
telomerase in vivo (66), and have demonstrated that FEN1
deﬁciency in mouse embryonic ﬁbroblasts leads to an
increase in telomere end-to-end fusions. In cancer cells,
FEN1 deﬁciency induces gradual shortening of telomeres,
but does not alter the single-stranded G-overhangs (66).
This is the ﬁrst evidence that FEN1 and telomerase phys-
ically co-exist as a complex and that FEN1 can regulate
telomerase activity at telomeres in mammalian cells (66).
A recent study shows that FEN1, but not exonuclease 1,
can cleave varying model substrates containing a telomeric
G-quadruplex structure, suggesting that FEN1 may be
important in resolution of G-quadruplex structures
during replication of telomere sequences (67). Because
FEN1 can cleave both DNA and RNA, we postulate
that FEN1 may also function to remove the telomerase
RNA template in the last cycle of telomere extension
(Figure 1).
REGULATORY MECHANISMS
Localization as a major means of functional regulation of
FEN1
Despite the wealth of information available on the
biochemical functions of FEN1 and its roles in genome
stability and cancer avoidance, cellular compartmentaliza-
tion and dynamics that correspond to FEN1’s involve-
ment in various DNA metabolic pathways have not
been fully elucidated. Previously, we demonstrated that
FEN1 migrates into the nucleus in response to DNA
damage and during S-phase of the cell cycle (Figure 2)
(11). Furthermore, primary sequence analysis of eukary-
otic FEN1 identiﬁed a bipartite C-terminal motif that is
rich in positively-charged amino acid residues as a
putative nuclear localization signal, which was validated
by site-directed mutagenesis (11). More recently, we found
that FEN1 super-accumulates in the nucleolus (Figure 2)
and plays a role in the resolution of stalled DNA replica-
tion forks that form at sites of natural replication fork
barriers (12).
High-resolution imaging of cells stained with
anti-FEN1 antibodies revealed that FEN1 is also present
in the mitochondria (Figure 2) (13,68). We conducted
ﬂuorescence microscopy on a C-myc-tagged FEN1
mutant protein (Y
83H) to clearly show that this mutant
protein localized to mitochondria and not to nuclei (13).
These data were complemented by cell fractionation
experiments, which identiﬁed FEN1 in the mitochondrial
extract. Further support for FEN1 migration into
the mitochondrion comes from the work of Kalifa
and Sia, demonstrating the mitochondrial localization
of yeast FEN1 using immunohistochemical and genetic
approaches (69).
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factors that are encoded in the nucleus, as the gene
products of the mtDNA genome are limited to
22 tRNAs, 2 rRNA subunits and 13 proteins involved
in energy production (70). All other genes required for
mitochondrial function are encoded in the nuclear
genome, and their gene products must be imported (70).
Recently, other DNA replication and repair proteins
encoded in the nuclear genome, in addition to FEN1,
were shown to be localized in mitochondria in addition
to the nucleus (13,71,72). Because reactive oxygen species
are mainly generated in mitochondria, mtDNA is pro-
foundly susceptible to oxidative damage, the accumula-
tion of which is positively correlated with aging and
age-related diseases like neurodegenerative disorders.
Studies of mtDNA damage have shown that a signiﬁcant
portion of oxidative damage occurs on the deoxyribose
moiety. Such damage results in the formation of
deoxyribolactone, which if repaired by short-patch BER,
gives rise to protein-DNA cross-links. Therefore, the
majority of deoxyribolactone products are preferentially
processed by LP-BER. More recently, we have shown
that immunodepletion of FEN1 or DNA2 nuclease
impairs the ability of mitochondrial extracts to process
model substrates representing intermediate structures
during RNA primer removal, suggesting that FEN1
plays a role in mtDNA replication as well. Because
FEN1 is the nuclease responsible for ﬂap cleavage in
RNA primer removal and LP-BER, its presence in the
mitochondria is not surprising. However, the mechanism
by which it enters the mitochondrial matrix is unknown,
as it is devoid of known canonical mitochondrial targeting
sequences. We suggest that FEN1, like DNA2 nuclease,
may be imported into mitochondria via an internal
mitochondrial targeting motif.
Protein–protein interaction: FEN1’s functional complexes
The types of proteins with which FEN1 interacts suggest
its pivotal role in several DNA metabolic pathways.
We therefore carried out an extensive investigation of
the network of all possible physical protein–protein inter-
actions (PPIs) of human FEN1 and its homologs in
Saccharomyces cerevisiae (Rad27) and C. elegans
(CRN-1). Manual curation of PPIs from the literature
began by species-speciﬁc identiﬁcation of PPIs through
the PPI database STRING (http://string-db.org). This
method identiﬁed 105, 137 and 42 PPIs from human,
S. cerevisiae, and C. elegans, respectively, with a default
conﬁdence of 0.4. We ultimately identiﬁed 34 PPI partners
of FEN1 that were previously evaluated by various
methods, including co-immunoprecipitation and yeast
two hybrid. Based on the known effects of these inter-
actions on the biochemical activities and biological func-
tions of FEN1, its interacting partners can be grouped
into four functional categories (Figure 3).
The ﬁrst category includes protein partners that assist
FEN1 in RNA primer removal during DNA replication.
In eukaryotic cells, DNA synthesis is primed by the
primase/polymerase-a (primosome), which synthesizes
the RNA/DNA initiator primer (73). After primer synthe-
sis, replication factor C (RFC) loads the homotrimeric
ring-shaped protein known as PCNA onto dsDNA.
PCNA acts as a sliding clamp molecular adaptor that
localizes bound proteins to DNA. When the processive
replisome encounters the downstream Okazaki fragment,
a portion of the RNA/DNA primer is displaced to
form a 50-ﬂap structure, which needs to be removed
prior to ligating the remaining DNA segments. FEN1
interacts with PCNA, Pol a/e, RPA, hnRNP A1 and
DNA ligase I for efﬁcient Okazaki fragment processing
(74–78). RPA has been reported to inhibit FEN1, based
on the ‘sequential nuclease cleavage’ model in yeast cells,
in which DNA2 and FEN1 sequentially cleave the RNA
primers (45).
FEN1 also interacts with members of the RecQ helicase
family, including WRN, BLM and RecQ5. The possible
physiological roles of these interactions with FEN1 in
DNA replication and replication fork rescue have been
discussed in detail elsewhere (59,79). In contrast to
PCNA, Wrn protein stimulates the GEN activity,
thereby cleaving the ssDNA region in the duplex DNA
molecule (10). In addition, there is evidence that forma-
tion of a functional FEN1/Wrn complex is important for
resolving stalled DNA replication forks. Moreover,
phenotypes associated with yeast DNA2 mutants can be
rescued by expression of BLM or WRN, which stimulate
FEN1 activity (59,80). Therefore, it is interesting to specu-
late that the complex formed between FEN1 and either
RecQ helicase is the functional homolog of DNA2.
Furthermore, Imamura and Campbell have postulated
that a helicase such as BLM may be necessary to facilitate
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Figure 2. Dynamic subcellular localization of FEN1. FEN1 localizes to
four distinct subcellular compartments in mammalian cells: cytoplasm,
mitochondria, nuclear plasm and nucleolus. In response to cell cycle
transitions and DNA damage, FEN1 dynamically migrates via four
different routes: (i) nuclear translocation from the cytoplasm, (ii) accu-
mulation in the nucleolus from the nuclear plasm; (iii) formation of
replication/DNA damage foci from the nuclear plasm and nucleolus
and (iv) mitochondrial import from the cytoplasm. The nuclease
domain of FEN1 is represented by an oval, and the C-terminus is
indicated as a zig-zag tail.
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RecQ helicases might coordinate formation and
FEN1-mediated removal of 50-ﬂap structures during
Okazaki fragment maturation. When dealing with the
ends of chromosomes, FEN1 interacts with proteins
involved in telomere stability, which include TRF2, Wrn
and TERT (7,66). Furthermore, FEN1 has also been
shown to interact with Chlr1, a member of the DEAD/
DEAH helicases in the chromosome cohesion complex
(81), which implies that FEN1 may play a role in
Figure 3. Protein–protein interactions mediate FEN1’s actions in different DNA metabolic pathways. FEN1 interactive proteins were categorized into
ﬁve functional groups: DNA replication, DNA repair, apoptotic DNA degradation, maintenance of telomere stabilities and post-translational modiﬁ-
cations, based on the known biochemical activities and pathways of these proteins. Protein–protein interactions (PPIs) of FEN1 that occur in mammalian
cells are colored in gray. The physical and functional interactions of FEN1 (Rad27) with Pol4 and FEN1 with Dnl4/Lif1, which are important for the
processing of DNA ends in S. cerevisiae (91,117), are colored in yellow. Two nucleases, CPS-6 and CRN-1, the C. elegans homologs of EndoG and FEN1,
respectively, have been implicated in mediating apoptotic DNA degradation in C. elegans (6,118) and are colored in blue. APEX1, AP endonuclease 1;
BLM, bloom syndrome protein; CDK1, cyclin-dependent kinase 1; CDK2, cyclin-dependent kinase 2; CPS-6, ortholog of human mitochondrial
endonuclease G (EndoG); CRN-1, cell-death-related nuclease family member (crn-1); CRN-3, cell-death-related nuclease family member (crn-3);
CRN-4, cell-death-related nuclease family member (crn-4); CRN-5, cell-death-related nuclease family member (crn-5); Cyclin A, cyclin A2; CYP-13,
cyclophilin homolog; DNA2L, DNA2-like helicase; Dnl4, DNA ligase IV homolog; EP300, E1A binding protein p300; FEN1, ﬂap structure-speciﬁc
endonuclease1;hCHLR1,DEAD/H(Asp-Glu-Ala-Asp/His)boxpolypeptide11;HMG1,high-mobilitygroupbox1;HNRNPA1,heterogeneousnuclear
ribonucleoprotein A1; Hus1, HUS1 checkpoint homolog; LIG1, DNA ligase 1; NEIL1, Nei endonuclease VIII-like 1; Nej1p, homologous to mammalian
XRCC4 protein; PCNA, proliferating cell nuclear antigen; POL a, DNA polymerase a-catalytic subunit; POL b, DNA polymerase b; POL d, DNA
polymerase d-catalyticsubunit;POL e,DNApolymerase e,catalyticsubunitA;Pol4,DNA polymeraseIV;PRMT5,proteinargininemethyltransferase 5;
Rad1, DNA repair exonuclease rad1 homolog; Rad17, homolog of human and S. pombe Rad1 and Ustilago maydis Rec1 proteins; RAD27, 50–30
exonuclease, 50-FEN; Rad9, DNA repair exonuclease rad9 homolog A; RFC, replication factor C; RPA, replication protein A; TERT, telomerase
reverse transcriptase; TRF2, telomeric repeat binding factor 2; WAH-1, worm AIF homolog; WRN, Werner syndrome ATP-dependent helicase; Solid
line,physicalandfunctionalinteractions;dashedlines,geneticinteractions;rightwardsarrow:stimulatorytotheenzymeactivities;multimap,inhibitoryto
the enzyme activity; reverse assertion, post-translational modiﬁcations.
Nucleic AcidsResearch, 2011, Vol.39,No. 3 787communicating between the DNA replication and
chromosome segregation machinery.
The second category of FEN1-interacting proteins is
DNA repair proteins. In mammalian cells, single base
lesions are repaired by single-nucleotide BER or
LP-BER. Apurinic endonuclease 1 (APE1) recognizes
the apurinic/apyrimidinic residues (AP) and cleaves 50 to
the AP sites after the actions of glycosylases such as Neil1,
thereby generating a nick on which Pol b is loaded (82,83).
If the lyase activity of Pol b cannot remove the deoxyri-
bose moiety after it has added the complementary nucleo-
tide to the free 30-hydroxyl, strand displacement synthesis
occurs, thereby creating a small 50-ﬂap (2–10nt) that must
be cleaved by FEN1 with subsequent ligation of the nick
to complete the repair (48). The role of FEN1 in LP-BER
is regulated and coordinated by physical interaction with
important BER components such as Pol b, APE1, Lig 1
and PCNA (82,84,85). The LP-BER protein Neil1 has also
been reported to interact and stimulate FEN1 nuclease
activities in vitro (83). Furthermore, WRN has recently
been shown in vitro to participate in LP-BER by
facilitating Pol b strand-displacement synthesis via its
helicase activity (86). Therefore, WRN’s interaction with
and stimulation of FEN1 may also be important for efﬁ-
cient 50-ﬂap removal in LP-BER. More recently, the
FEN1/WRN complex was implicated in replication fork
rescue through break-induced repair (10). FEN1 was also
shown to interact with the human Rad9-Rad1-Hus1
checkpoint complex (9-1-1 complex) (87–89), a
heterotrimeric protein that is similar to the PCNA
toroidal sliding-clamp. Formation of this complex is
stimulated by Rad17/RFC in yeast in a p53-dependent
manner (90). Although the 9-1-1 complex is unable to
stimulate Pol d synthesis like PCNA, it can stimulate the
FEN activity of FEN1 on ﬂap substrates (89). The role of
this interaction in vivo remains to be shown. Because 9-1-1
accumulates at sites of DNA damage, the interaction of
FEN1 with 9-1-1 is likely important for stimulating
FEN-1 activity for DNA repair. Recently, ScFEN1
(RAD27) was shown to interact with Pol4 and Dnl4/
Lif1, which are components of the non-homologous
end-joining dsDNA break repair pathway (91). The
various functional interactions between FEN1 and
proteins involved in different DNA repair pathways
indicates its wide range of roles in DNA repair.
The third category consists of apoptotic proteins, and is
exempliﬁed by Endo G. Parrish et al. (6) demonstrated
that CRN-1, the C. elegans FEN1 homolog, in association
with CPS-6 (Endo G), mediates stepwise DNA degrad-
ation during apoptosis. This is the ﬁrst example in a bur-
geoning ﬁeld that is sure to lead to the identiﬁcation of
additional apoptotic FEN1-interacting proteins across
many species. Furthermore, Parrish et al. (6) have
identiﬁed seven novel nucleases that play a role in apop-
totic DNA fragmentation in C. elegans. Most of these
proteins form a complex called a ‘degradosome’ to efﬁ-
ciently break down the chromosomes and nucleic acids
during development (6). Association of FEN1 with apop-
totic proteins such as Endo G may be a key mechanism to
switch FEN1’s role from DNA replication and repair to
apoptotic DNA fragmentation. FEN1 interaction with
Endo G also greatly enhances its minor GEN and EXO
activities, important for disposal of apoptotic DNA.
The ﬁnal category of FEN1-interaction partners are
those proteins that post-translationally modify FEN1,
including p300, Cdk1-Cyclin A, Cdk2-Cyclin A and
PRMT5 (14–16). These proteins and their involvement
in FEN1 function are discussed in detail in the next
section.
Despite the wide variety of proteins, many of these PPIs
are predominantly mediated via FEN1’s C-terminal exten-
sion (88). In the absence of a protein partner, the extended
C-terminus is predicted to be intrinsically disordered
(DisEMBL http://dis.embl.de and PONDR http://www.
pondr.com); thus, FEN1 joins a growing list of proteins
that are mostly folded, but have regions of local disorder
that mediate PPIs (92,93). Locally disordered regions of
proteins are known to undergo disorder-to-order transi-
tions upon binding a target. This allows for the formation
of complexes with high speciﬁcity and relatively low
afﬁnity, which is important for proteins that must
initiate an action and then dissociate when ﬁnished with
that action. The disordered region of a protein also
confers the ability to interact with multiple protein
partners and modifying enzymes thereof using the same
motif (92,93). Thus, the nucleolytic action of FEN1 in the
cell is likely directed by different protein partners by
binding initially to the C-terminal region of FEN1 as a
means to sequester the protein to speciﬁc sites in the nu-
cleoplasm. Although high afﬁnity interaction is mediated
by the extended C-terminus, a crystal structure of FEN1
in complex with PCNA revealed that core nuclease
domain interactions also exist (94), but are probably too
weak to mediate interactions strong enough to be detected
by non-equilibrium binding assays. Therefore, many of
the proteins identiﬁed as FEN1 interaction partners
probably utilize the extended C-terminus, but interactions
are likely not exclusive to this region.
Recently, we have determined the residues critical for
FEN1 interaction with its ﬁve different interactive
partners (88). Consistent with the role of a disordered
region, each interactive partner of FEN1 requires a
distinct combination of extended C-terminal residues for
binding. For instance, the Q337, L340, D342, F343, F344,
V346, S353 and S352 residues within and next to the PIP
box of FEN1 are essential for the FEN1/PCNA inter-
action, whereas the K366, K367, K375, R378 and K380
residues are required for the FEN1/WRN interaction (88).
On the other hand, the lysine residues, including K375 and
K380, of FEN1 have been shown to be acetylated by p300
(14). The distinct PPI signatures at the C-terminal region
of FEN1, together with post-translational modiﬁcations,
may provide a mechanism to allow FEN1 to interact with
different proteins and be recruited to different DNA meta-
bolic machineries in response to DNA damage.
Simple deletion of a gene is not a high-resolution
approach to study the biological signiﬁcance of a PPI,
because a single protein may interact with multiple
partners. In addition, the complete deletion of an essential
gene is often embryonically lethal in animals. Therefore,
to obtain high-resolution biological information for a
speciﬁc interaction, we take an alternative approach of
788 Nucleic Acids Research, 2011,Vol. 39,No. 3knocking-in rather than knocking-out identiﬁed muta-
tions that speciﬁcally disrupt one interaction. Phe343
and Phe344 of FEN1 are key residues that mediate the
interaction between the PIP-box of FEN1 and the
interdomain connector loop motif of PCNA (49,95)
(Figure 4A). Substitution of these two residues with two
Ala residues (FFAA) abolishes the high afﬁnity physical
interaction between FEN1 and PCNA (49,95). Disruption
of this interaction does not affect the in vitro nuclease
activity of FEN1. Instead, it disrupts precise
PCNA-mediated coordination among the polymerase,
nuclease and ligase during the processes of Okazaki
fragment maturation and LP-BER (Figure 4B). As a con-
sequence, the FFAA mutation causes failure of recruit-
ment of FEN1 to the replication foci and inhibits
processing of Okazaki fragments, even when present
only in the heterozygous form. Furthermore, heterozy-
gous FFAA mutant mice develop aneuploidy-associated
cancers, similar to what has been observed in human
cancers (L. Zheng et al. unpublished data).
Post-translational modiﬁcations: a primary event for
functional regulation
FEN1 is a target for at least three post-translational modi-
ﬁcations in vivo: phosphorylation (15), acetylation (14,96)
and methylation (16). The Cdk1-cyclin A or Cdk2/cyclin
E complex phosphorylates FEN1 at Ser187 in late
S phase, and in vitro Cdk1-cyclin A phosphorylation of
FEN1 reduces the endonuclease and exonuclease activities
of FEN1 without affecting DNA binding (15). In
addition, phosphorylation of FEN1 abolishes PCNA
binding (15). Serine phosphorylation is hypothesized to
be one of the cell cycle regulatory mechanisms of FEN1
activities, and Ser187 is the only FEN1 residue that has
been shown to be phosphorylated (15). In late S phase,
phosphorylation may be used to block FEN1’s nuclease
activities and its recruitment to the DNA replication
site by PCNA. Therefore, this phosphorylation may con-
tribute to halting the replication machinery, thereby
ensuring exit from S phase (15). In addition, phosphoryl-
ation of FEN1 was also shown to regulate its nucleolar
localization and to inﬂuence the dynamic roles of FEN1 in
ribosomal DNA replication and damage repair (12). In
response to UV irradiation and upon phosphorylation,
FEN1 migrated to the nucleoplasm to participate in the
resolution of UV crosslinks on DNA, most likely through
the concerted action of its EXO and GEN activities (12).
Based on yeast complementation experiments, the
Ser187Asp mutation, which mimics constitutive phos-
phorylation, abolishes nucleolar accumulation of FEN1.
On the other hand, replacement of Ser187 by Ala, which
eliminates the only phosphorylation site, causes retention
of FEN1 in the nucleoli. Both mutations cause UV sensi-
tivity, impair cellular UV damage repair capacity and
reduce overall cellular survival (12).
Furthermore, the methylation and phosphorylation of
FEN1 offer a possible answer to one critical question of
how FEN1 can efﬁciently bind to PCNA and DNA sub-
strates, and then dissociate once the nuclease reaction is
complete to avoid blockage of Lig1 reaction during DNA
replication in the S phase of the cell cycle. Our recent
discovery sheds light on this puzzle. We demonstrated
that FEN1 is methylated at the R192 residue, and this
methylation prevents FEN1 phosphorylation at the S187
residue (16). The methylated form of FEN1 interacts with
PCNA, but the phosphorylated form of FEN1 causes
prompt dissociation from PCNA, providing a mechanism
for the nuclease to dynamically associate with and dissoci-
ate from PCNA, and thus, the DNA substrate (16). Based
on our data, we postulate that in the early stages of
Figure 4. Model of the PCNA-mediated sequential actions of Pol d, FEN1 and Lig I. (A) Structural basis for FEN1/PCNA interactions. Three
dimensional structure demonstrating that F343 and F344 of FEN1 are key residues that mediate the physical interaction between FEN1 and PCNA.
The structural model was based on crystal structures of the FEN1/PCNA complex (36,94). IDCL: interdomain connector loop. (B) Sequential
recruitment of Pol d, FEN1 and Lig 1 via PCNA interaction. The PCNA trimmer encircles the DNA duplex and serves as a platform for sequential
recruitment of Pol d, FEN1 and Lig I, which are key enzymes in Okazaki fragment maturation.
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methylated form, which enables it to replace Pol d and
access PCNA and the ﬂap structure. Upon cleavage of
the RNA primer ﬂap, FEN1 is demethylated, thereby
allowing the nuclease to be phosphorylated by a cell
cycle-dependent kinase, cdk1 or cdk2. Phosphorylation
of FEN1 causes the nuclease to fall off PCNA and the
DNA nicks, leading to Lig1 recruitment and DNA
ligation. However, the mechanism by which FEN1 is
demethylated remains to be investigated.
Another intriguing question is how FEN1 phosphoryl-
ation inﬂuences the FEN1/PCNA interaction. Previous
studies have demonstrated that phosphorylation may
induce conformational changes and modulates protein–
protein interactions (97–99). We suggest that phosphoryl-
ation of the S187 residue adds a negative charge to the
embedded S187 residue, leading to exposure of the
phosphorylated S187 residue. This may in turn stabilize
a conformation whereby the positively-charged
C-terminal random coil folds back to interact with the
negatively-charged nuclease core domain, masking the
interface for PCNA binding. As a consequence,
phosphorylated FEN1 fails to interact with PCNA. This
hypothesis is consistent with a previous study showing
that phosphorylation of PTEN induced conformational
changes that led to the masking of the PZD binding
domain and disruption of the interaction between PTEN
and PZD domain-containing proteins (98). In addition,
the theory of phosphorylation-induced conformational
change can also explain why FEN1 phosphorylation at
the S187 residue abrogates FEN1 nucleolar localization.
FEN1 co-localizes with WRN and nucleolin (C23) in
nucleoli (12), and the interactions between FEN1 and nu-
cleolar proteins such as WRN and nucleolin are important
to retain the nuclease within nucleoli. However, because
the C-terminal region is also the key element for inter-
action with WRN, folding back of the C-terminal region
in phosphorylated FEN1 may also disrupt FEN1 inter-
action with WRN or other proteins, leading to migration
out of nucleoli.
FEN1 can also be post-translationally modiﬁed by
acetylation (14,100). Hasan et al. (14) observed an
acetylated form of FEN1 in HeLa cells, and the amount
of this form was enhanced upon UV treatment. The p300
acetyltransferase interacts with FEN1 in vitro and in vivo
and acetylates FEN1 in vitro (14). Mass spectrometry
analysis of in vitro acetylated FEN1 revealed four lysine
sites located the very C-terminus of FEN1 that could be
acetylated (K354, K375, K377 and K380) (14). In vitro
acetylated FEN1 had reduced PCNA-independent
nuclease activity and DNA binding afﬁnity, but intact
PCNA-binding and stimulating capacity (14,96). The in-
hibitory effect of FEN1 acetylation on its enzymatic
activity is puzzling, considering that the nuclease activities
of FEN1 are important for processing different DNA
intermediate structures in various DNA metabolic
processes. Hubscher and colleagues suggested that FEN1
acetylation functions to avoid premature processing of
Okazaki fragments (14). Inhibition of FEN1 would
promote the formation of longer ﬂaps that require the
two-nuclease pathway (DNA2-FEN1) (14). In support
of this, Bambara and colleagues showed that p300 acetyl-
ates Dna2, thereby stimulating its 50–30 endonuclease,
helicase and DNA-dependent ATPase activities, and
enhancing its binding with DNA substrates (35). More
recently, three acetylation sites, K80, K267, K375, were
identiﬁed in FEN1 puriﬁed from human cells (100).
Among these three in vivo acetylation sites of FEN1,
two are different from the in vitro identiﬁed sites. The
functional roles of these new acetylation sites remain
unknown. Because K267 is close to the downstream
dsDNA binding region, it could regulate DNA binding.
Like K267, K80 is solvent exposed, but on the opposite
side of the DNA binding interface. Therefore, like acetyl-
ation of K375 in the extended C-terminus, these acetyl-
ations may regulate PPIs.
FEN1 MUTATIONS LINK THE MUTATOR GENE TO
CANCER
Functional deﬁciency of FEN1 has been suggested to
cause genomic instability and cancer predisposition, and
the importance of FEN1 in the prevention of oncogenesis
has recently been studied (40). In mice, homozygous
knockout of FEN1 is embryonically lethal, consistent
with the observation that Fen1 null mouse blastocysts
are arrested in S phase (41). Fen1 heterozygous
knockout mice are viable and appear to be free of
disease. However, FEN1 heterozygous knockout mice
that are also heterozygous for the APC gene develop
adenocarcinomas that result in decreased survival (40).
These results suggest that FEN1 is a tumor suppressor
gene (101).
The initiation and development of cancer is considered
a microcosm of the evolutionary process, a hallmark of
which is the accumulation of numerous genetic
abnormalities in multiple genes (102,103). Inherited muta-
tions of speciﬁc genes, such as BRCA1 or BRCA2, and
mismatch repair genes, which result in susceptibility to
breast cancer and colorectal cancer, respectively, account
for only 20% of cancers (104). In most cancers, genetic
changes arise by somatic mutations (104). Based on our
understanding of the FEN1 nuclease, we predict that there
could be four classes of FEN1 mutations that may be
identiﬁed in cancer cells, which might impair (i) the
nuclease activities, (ii) compartmentalization, (iii) pro-
tein–protein interactions or (iv) post-translational modiﬁ-
cation sites. Thus far, we have identiﬁed FEN1 mutations
that eliminate the EXO and GEN activities, but retain the
FEN activity (9). To demonstrate the etiological signiﬁ-
cance of these somatic mutations, we established the ﬁrst
mouse line harboring the E160D mutation, which inter-
feres with FEN1 binding to the magnesium ion respon-
sible for substrate binding and speciﬁcally abrogates the
EXO and GEN activities of FEN1 (9,105). This mouse
line was used to model the FEN1 mutations identiﬁed in
human cancers (9). Selective elimination of nuclease
activities in this mouse line led to frequent spontaneous
mutations and accumulation of incompletely digested
DNA fragments in apoptotic cells. Two independent
studies demonstrated that the E160D mutant mice are
790 Nucleic Acids Research, 2011,Vol. 39,No. 3susceptible to the development of cancers (9,106). We
further revealed that the mutator phenotype results in
the initiation of cancer, whereas chronic inﬂammation
promotes cancer progression (9). These ﬁndings support
the view that FEN1 is required for genome stability and
can therefore be considered a tumor suppressor gene
(101).
The onset of tumorigenesis is rooted in the accumula-
tion of genetic aberrations, such as point mutations, frame
shifts, chromosomal defects and microsatellite expansions
and contractions. The sequential progression from normal
to malignant cells is accompanied by an increase in these
alterations in cells, which continues within the
heterogeneic tumor cell population during tumor
growth. The mechanisms by which these errors accumu-
late are thought to be due in part to damage acquired by
genes involved in genomic stability. This instability would
result in further mutations to regulatory genes. The in-
volvement of FEN1 in controlling genomic stability
through multiple metabolic actions suggests that function-
al loss of FEN1 through mutations would facilitate
further tumor mutagenesis.
Deﬁciency in the activity of FEN1 nuclease to degrade
apoptotic DNA, on the other hand, can result in produc-
tion of anti-DNA auto-antibodies and subsequently lead
to autoimmune-related chronic inﬂammation, which may
promote cancer progression, possibly via activation of
NF-kB (9). The FEN1 E160D mutant mouse model will
be useful for resolving additional issues in cancer biology,
including the identiﬁcation of essential mediators of
chronic inﬂammation in lung tissue; the determination of
whether suppression of inﬂammatory responses by
altering cytokine proﬁling with NF-kB inhibitors, or by
anti-inﬂammatory agents, reduces cancer incidence; and
the establishment of whether E160D mutant mice, deﬁ-
cient in DNA repair and apoptotic DNA degradation,
are more susceptible to tobacco-induced tumorigenesis.
Answering these questions will be important to designing
new cancer therapeutic regimens that act by the suppres-
sion of speciﬁc inﬂammatory responses.
Contrary to FEN1’s role as a tumor suppressor, several
studies from our and other groups suggest that FEN1 may
also be required to support the growth and progression of
cancers. FEN1 is detectable in all proliferative tissues, but
is at very low levels in quiescent cells (107). Furthermore,
FEN1 expression is elevated in cultured lung cancer cells
as compared to normal cells (108), and FEN1 is
over-expressed in many cancer types (109–112). In
addition, the level of FEN1 expression in tumor tissues
has been correlated with increased tumor grade and
aggressiveness (109). Because FEN1 plays an essential
role in DNA replication, it is thought that high levels of
FEN1 are required to support hyperproliferation of
cancer cells. Consistent with FEN1 over-expression in
cancer tissues, several breast cancer cell lines have
increased FEN1 expression at the mRNA and protein
levels that correlate with decreased CpG2 methylation
levels in comparison to matched normal tissues (111).
Whether the epigenetic changes in the promoter region
of FEN1, as mentioned above, occur in cancers other
than breast cancer remains to be determined.
CONCLUDING REMARKS
Compelling evidence from in vitro and in vivo studies in-
dicates that FEN1 is a multifunctional nuclease that par-
ticipates in distinct DNA metabolic pathways.
Interestingly, FEN1 can promote cancer in two very dif-
ferent ways: (i) mutation of the gene can result in genomic
instability and initiate malignant transformation and
(ii) overexpression of the gene confers a growth advantage
to tumors. In response to the latter way to promote
cancer, FEN1 has been suggested as cancer therapeutic
target (113–116). However, like other current
chemotherapeutics, inhibitors of FEN1 will likely be
fraught with side effects and have the potential to propa-
gate or even initiate new cancers. Nonetheless, such work
should continue to increase our clinical cancer arsenal,
with eventual hopes of novel drug delivery mechanisms.
Despite our substantial knowledge of FEN1 structure,
biochemical activities and biological functions, many
questions remain to be addressed. For instance, how
does FEN1 dynamically translocate from one location to
another; and in particular, how is FEN1 recruited to rep-
lication and repair foci to execute ﬂap cleavage and sub-
sequently dissociate from DNA substrates to avoid
interference with Lig1-mediated DNA ligation? What is
the mechanism for phosphate diester cleavage? How
FEN1 is demethylated? How does FEN1 avoid constant
phosphorylation and failure to interact with PCNA? How
does FEN1 migrate into the mitochondrion for its
function? Do FEN1 mutations that abolish FEN1
post-translational modiﬁcations, localization or a speciﬁc
protein–protein interaction cause cancer and/or other
diseases? Future studies will ﬁll in the knowledge gaps
regarding this structure-speciﬁc nuclease.
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